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Real-world questions and concerns about
disease-modifying antirheumatic drugs
(DMARDs): a retrospective analysis of
questions to a medicine call center
Hiba EL Masri1* , Samantha A. Hollingworth1 , Mieke van Driel2 , Helen Benham3,4 and
Treasure M. McGuire1,5,6
Abstract
Background: Disease-modifying antirheumatic drugs (DMARDs) have transformed the treatment of numerous
autoimmune and inflammatory diseases but their perceived risk of harm may be a barrier to use.
Methods: In a retrospective mixed-methods study, we analysed conventional (c) and biologic (b) DMARDs-related
calls and compared them with rest of calls (ROC) from consumers to an Australian national medicine call center
operated by clinical pharmacists from September 2002 to June 2010. This includes the period where bDMARDs
became available on the Pharmaceutical Benefits Scheme, the government-subsidized prescription medicines
formulary. We compared caller and patient demographics, enquiry types and motivation to information-seek for
both cDMARDs and bDMARDs with ROC, using a t-test for continuous data and a chi-square test for categorical
data. We explored call narratives to identify common themes.
Results: There were 1547 calls involving at least one DMARD. The top three cDMARD enquiry types were side
effects (27.2%), interactions (21.9%), and risk versus benefit (11.7%). For bDMARDs, the most common queries
involved availability and subsidized access (18%), mechanism and profile (15.8%), and side effects (15.1%). The main
consumer motivations to information-seek were largely independent of medicines type and included: inadequate
information (44%), wanting a second opinion (23.6%), concern about a worrying symptom (18.8%), conflicting
information (6.9%), or information overload (2.3%). Question themes common to conventional and biological
DMARDs were caller overemphasis on medication risk and the need for reassurance. Callers seeking information
about bDMARDs generally overestimated effectiveness and focused their attention on availability, cost, storage, and
medicine handling.
Conclusion: Consumers have considerable uncertainty regarding DMARDs and may overemphasise risk. Patients
cautiously assess the benefits and risks of their DMARDs but when new treatments emerge, they tend to
overestimate their effectiveness.
Keywords: Disease-modifying antirheumatic drugs, Information services, Patients, Help-seeking behavior OR
information-seeking behaviour, Drug information services, Patient perspective, Concern, Expected outcome
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Background
The clinical trial evidence for disease modifying antirheu-
matic drugs (DMARDs) to treat various autoimmune dis-
eases emerged in the 1980s for conventional (cDMARDs)
and in the 1990s for biologic (bDMARDs). The latter only
became widely accessible to the Australian public with list-
ing on the Pharmaceutical Benefits Scheme for rheumatoid
arthritis (RA) in 2003 [1]. DMARDs have revolutionized
the management of conditions such as RA and other auto-
immune diseases [2–4]. Although a growing body of evi-
dence demonstrates that their use is relatively safe [5],
consumers report information gaps and express concerns
related to the perceived aggressive and harmful nature of
DMARDs [6]. Patients on DMARDs have complex and
often evolving perceptions about their long-term side ef-
fects and efficacy [7–10]. Concerns and beliefs about
DMARDs can affect adherence to treatment and eventually
clinical outcomes [11, 12]. Stronger beliefs in the necessity
of DMARDs are associated with better adherence, while in-
creased concerns about their safety correlates with poorer
adherence [13, 14]. Sociodemographic variables, including
age, education, ethnicity, and income are also found to im-
pact patients’ perceptions about DMARDs. Younger, more
educated, and patients with higher income have a greater
risk tolerance [15] whereas black patients are found to be
more risk averse than non-black patients [16].
Although previous studies have enabled a partial under-
standing of patients’ perspectives on DMARDs, we know lit-
tle about the information gaps and concerns of Australian
consumers, particularly as clinician prescribing has evolved
from the use of only cDMARDs to include bDMARDs [15,
16]. This study therefore aims to characterise real-world
questions and concerns about DMARDs, both conventional
and biologic, through the analysis of calls made to a national
medicine call center (MCC) in Australia over an eight-year
timeframe, inclusive of the period where bDMARDs
became available on the Pharmaceutical Benefits Scheme
(PBS) which provides government-subsidized prescription
medicines to citizens and permanent residents.
Methods
Data collection and management
A retrospective, mixed methods analysis of consumers’ en-
quiries to a national consumer MCC about the use of both
conventional and biologic DMARDs was undertaken. Calls
were extracted with questions relating to DMARDs from
NPS MedicineWise (formerly National Prescribing Service
(NPS) Medicines Line), operated by clinical pharmacists at
Mater Health, Brisbane between September 2002 and June
2010. The service was funded by NPS to serve consumers
throughout Australia for the cost of a local call. As data
were originally collected for routine health service without
specific a priori research goals, this research followed the
REporting of studies Conducted using Observational
Routinely-collected health Data (RECORD) guideline [17],
an extension of the STrengthening the Reporting of OBser-
vational studies in Epidemiology (STROBE) guidelines
[18].
The details of each call were captured on a standar-
dised form and entered into a Microsoft Access data-
base. These included demographic characteristics of
both patient and caller, enquiry type, relationship of
caller to patient, postcode, and motivation to call. For
each call, up to three generic medicines relating to the
question were recorded and categorised by the Anatom-
ical Therapeutic Chemical (ATC) classification of medi-
cines [19]. The pharmacists also noted on the forms the
questions asked, using the same terms and wordings of
the consumers. We extracted all calls related to
DMARDs (L04AX for methotrexate and leflunomide,
M01CB for auranofin, A07EC for sulfasalazine, P01BA
for chloroquine and hydroxychloroquine, and L04AB for
all the bDMARDs). The remaining calls were classified
as ‘rest of calls’ (ROC).
Quantitative analysis
DMARD-related calls were analyzed and compared with
ROC over an eight-year period. Caller and patient demo-
graphic characteristics, enquiry types and caller motiva-
tions to help-seek were compared between DMARD
(conventional, biologic, and combined) calls and ROC
using a t-test for continuous data and a chi-square test for
categorical data. Any difference with a two-sided p-value <
0.05 was considered statistically significant. When testing
statistical significance versus ROC, p values were adjusted
using Bonferroni correction to minimize the risk of type I
errors [20]. Caller postcodes from each cohort were
mapped to the Accessibility/Remoteness Index of Australia
(ARIA) which determines the remoteness of areas from
service centres [21, 22]. The proportion of calls from each
ARIA were compared with Australian Bureau of Statistics
population data to obtain relative call frequencies
expressed as a ratio [21, 22]. We analyzed the quantitative
data using IBM SPSS Statistics 25 [23].
Narrative analysis
The narratives associated with call questions that were
available electronically were thematically analyzed and
coded through an interactive and iterative process
undertaken by two investigators independently (TM and
HM) [24]. Codes were compared, discussed, and col-
lapsed into major and minor themes, and any associated
sub-themes. A theme was considered major if it consti-
tuted 10% or more of all DMARD narratives. A theme
emerging from at least 1% of all narratives (and less than
10%) was considered a minor theme; while themes for
less than 1% of narratives were not considered in the re-
sults. For major themes, we captured any substantive
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differences in the profile between cDMARDs and
bDMARDs.
Results
Demographics and quantitative analysis
Of the 123,217 calls to the MCC, 1547 involved at least
one DMARD, with half (50.6%) including methotrexate
alone or in combination with a bDMARD. Hydroxychlor-
oquine, sulfasalazine, and leflunomide were the next most
common cDMARDs (14.6, 14.5, and 7.8%). One in five en-
quiries concerned a bDMARD including etanercept, adali-
mumab, infliximab, and rituximab (7.4, 5.4, 3.2, and 3.1%).
DMARD callers, as well as patients, were predominantly
female (82.4 and 78.1%), with most calls (79%) received
from patients themselves (Table 1). The mean age of cal-
lers was older for DMARDs than for ROC (53.63 ± 17.76
vs. 46.82 ± 23.785 years). There was a significantly higher
proportion of partners and family members calling to en-
quire specifically about a bDMARD than for ROC (28.9%
vs. 14.5%). DMARD callers hailed from all Australian
states and territories and across metropolitan, rural and
remote areas (Table 1).
The top three enquiry types for all DMARD calls in-
volved questions about medicines safety: side-effects
(25.2%), interactions (19.4%), and risk/benefit assessment
and comparison among DMARDs (12.1%), all signifi-
cantly higher than in ROC (Table 2). Other frequent en-
quiries for both DMARDs and ROC included
mechanism or profile of action of the medicine, as well
as the indication or use as a treatment option. There
was a different ranking of key enquiry types for
bDMARDs alone excluding the most common: enquiries
on side effects (15.1%). Calls for bDMARDs frequently
focused on consumers wanting to understand how these
medicines worked to effectively treat various conditions:
mechanism/profile of action (15.8%), indication and
treatment (10.8%), efficacy (5.8%), or to enquire about
logistical issues such as availability (11.2%), cost and sub-
sidized access (8.2%), identification and/or formulation
(4.7%), and stability, storage, and disposal (4.7%). The
Table 1 Demographics and characteristics of national MCC calls, DMARD-related versus ROC
Characteristic All DMARDs
(n = 1547)
cDMARDs
(n = 1269)
bDMARDs
(n = 278)
ROC
(n = 121,709)
Gender of the caller (%)
Female 82.4† 83.8† 74.9‡ 76.7
Male 17.6† 16.2† 25.1‡ 23.1
Missing – – – 0.2
Gender of the patient (%)
Female 78.1† 80.4† 65.6†‡ 68.3
Male 21.8† 19.5† 34.3†‡ 31.4
Missing 0.1 < 0.1 < 0.1 0.3
Age of the patient 53.63† 53.62† 52.74† 46.82
Mean (± SD) years (±17.76) (±17.89) (±17.44) (±23.75)
Missing (%) 0.45% 0.39% 0.36% –
Relationship of the caller (%)
Self 79.0† 81.2† 67.8‡ 71.3
Partner 7.2† 6.5† 10.9†‡ 1.7
Child 5.7† 5.4† 7.5†‡ 2.6
Other family or friend 5.6† 4.7† 10.5‡ 10.2
Other 2.5 2.5 3.3† 1.9
ARIA relative call frequency
Highly accessible 1.23 1.23 1.20 1.24
Accessible 0.50 0.50 0.55 0.46
Moderately accessible 0.39 0.39 0.38 0.32
Remote 0.34 0.34 0.96†‡ 0.69
Very remote 0.44 0.59 0 0.73
Missing (% of calls) 2.5 2.4 2.9 2.7
ARIA The Accessibility/Remoteness Index of Australia
† p < 0.05 versus ROC, with Bonferroni correction
‡ p < 0.05 versus cDMARDs
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major consumer motivations to information-seek regard-
ing DMARDs were largely independent of medicines
type (Table 2) and were prompted by inadequate infor-
mation (44%), needing a second opinion (23.6%), con-
cern about a worrying symptom (18.8%), conflicting
information (6.9%), or information overload (2.3%).
Many callers were driven to help-seek due to inadequate
information about bDMARD (57.7% of calls).
Narrative analysis
There were 724 call narratives that included a DMARD,
but 43 narratives contained questions that focused on other
medicine(s) used or of interest to the patient and were
excluded from the analysis. Thematic analysis of the
remaining 681 narratives revealed four major themes, each
including several sub-themes, and four minor themes
(Table 3).
Callers’ primary concerns about DMARDs, whether
conventional or biological, centred on medication safety,
accounting for more than a quarter (26.9%) of all narra-
tives. Many callers sought clarification as to whether a
symptom being experienced was a side effect caused by
their DMARD. Among these narratives, there were ques-
tions such as “Can methotrexate cause facial skin lesions
Table 2 Enquiry types and motivations to call for DMARDs versus ROC
All DMARDs
(n = 1547)
(%)
cDMARD
(n = 1269)
(%)
bDMARDs
(n = 278)
(%)
ROC
(n = 121,709)
(%)
Enquiry type
Side-effects 25.2† 27.2† 15.1†‡ 19.6
Interaction 19.4† 21.9† 6.5†‡ 15.1
Risk/Benefit & comparison 12.1† 12.5† 9.7‡ 8.3
Mechanism / Profile 9.5† 8.4 15.8†‡ 7.0
Indication & treatment 10.5 10.5 10.8 11.9
Dose & administration 6.0 6.7 2.5†‡ 7.9
Efficacy 3.1 2.8 5.8†‡ 2.8
Availability 3.0 1.4 11.2†‡ 2.6
Pregnancy & lactation 2.9† 3.1† 1.8† 8.6
Cost and PBS access 2.0 0.7 8.2†‡ 1.4
Identification / Formulation 1.9 1.2 4.7‡ 3.4
Stability/Storage/Disposal 1.3 0.6 4.7†‡ 0.9
Abuse and withdrawal 1.4 1.5 0.4† 3.4
Generics 0.4 0.3 0.7 0.8
Vaccination 0.7 0.7 0.7 1.9
Outside service brief (e.g. 0.1 0.1 0 1.5
poisons query)
Non-medicines issue 0.6 0.5 1.1 2.
Motivation to call
Inadequate information 44.0 44.0 57.7†‡ 46.6
Second opinion 23.6 23.6 18.4†‡ 23.5
Worrying symptom 18.8 18.8 13.4†‡ 17.8
Conflicting information 6.9† 6.9† 1.7†‡ ~ 0
Information overload 2.3 2.3 1.7 1.2
CMI 0.9 0.9 0.1 0.5
Forgot information 0.7 0.7 1.3 0.1
Media 1.2 1.2 3.4†‡ 0.9
Health professionals 0.5 0.5 0.8 6.3
Other 1.1 1.1 1.7 1.7
PBS Pharmaceutical Benefits Scheme, CMI Consumer Medicines Information
† p < 0.05 versus ROC, with Bonferroni correction
‡ p < 0.05 versus cDMARDs
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Table 3 Themes emerging from the narrative analysis of DMARDs calls
Themes All DMARDs
% (n = 681)
cDMARDs
% (n = 591)
(%)
bDMARDs
% (n=90)
(%)
Major themes & subthemes
1. Concern about medication safety 26.9 28.4 20.8
1.1. Clarification on potential side effect of a specified DMARD
“Will methotrexate cause hair loss?”
20.2 21.0 16.8
1.2. Information on the general safety of a specified DMARD
“What are the side effects of adalimumab?”
4.0 4.3 2.4
1.3. Reassurance on the use of a specified DMARD
“What are the risks of taking methotrexate as I am worried about taking it after the things I read on the internet?”
2.7 3.1 1.6
2. Seeking information on potential interactions with a specified DMARD 22.4 25.6 8.0
2.1. Seeking information on potential interactions of medicines with a specified DMARD
“Can hydroxychloroquine be taken with diclofenac?”
16.9 19.2 6.4
2.2. Seeking information on potential interactions of complementary medicines with a specified DMARD
“Can I take St john’s wort if I am on Mabthera (rituximab)?”
3.5 4.1 0.8
2.3. Lifestyle while on a specified DMARD
“Would there be an interaction between methotrexate and some alcohol I had at Christmas?”
1.6 1.9 0.0
2.4. Seeking information on potential interactions of a specified DMARD with food
“Any interactions between food and Humira (adalimumab) injection?”
0.4 0.4 0.8
3. Seeking a therapeutic strategy 13.0 14.7 4.0
3.1. Seeking a therapeutic strategy regarding the timing, dose, and administration of a specified DMARD
“Do I inject methotrexate intramuscularly or subcutaneously?”
7.5 8.0 3.2
3.2. Seeking a therapeutic strategy regarding dosing and timing of concomitant medicines to DMARD therapy
“What is the normal dose of folic acid when I am also on methotrexate 20 mg per week?”
1.0 1.0 0.0
3.3. Seeking a therapeutic strategy for managing withdrawal and/or reintroduction of a specified DMARD
“Can he stop methotrexate suddenly or does he have to do so gradually?”
2.6 3.2 0.0
3.4. Seeking a therapeutic strategy regarding the management of an adverse event and/or the continuation
of DMARD therapy in case of an occurred adverse event
“What can I do if I’ve experienced hives and irritation since starting adalimumab?”
1.5 1.6 0.8
3.5. Seeking a therapeutic strategy to manage a DMARD therapy before and/or after a procedure or an
elective surgery
“When should I cease meloxicam and sulfasalazine before surgery?”
0.7 0.9 0.0
4. Seeking information on a specified DMARD 10.1 4.9 33.6
4.1. Seeking general information on a specified DMARD
“Can you please provide me with information on hydroxychloroquine?”
4.4 3.6 8.0
4.2. Seeking information on a specified DMARD in response to media
“Disabled friend in his 70s saw a TV documentary on a new drug for arthritis- what is it?”
2.3 0.2 12.0
4.3. Seeking information on the availability, cost, and logistics to access a specified DMARD
“How can I obtain an emergency supply of Enbrel (etanercept) when my specialist is away?”
1.9 1.1 5.6
4.4. Seeking information on the restrictions and requirements to obtain subsidized DMARD
“Why can’t my 16-year-old nephew get Humira (adalimumab) on the PBS?”
1.5 0.2 8.0
Minor themes
1. Quantifying the benefit and harm of a specified DMARD
“What are the risks verse benefits of taking methotrexate for the treatment of psoriasis?”
7.5 7.5 7.2
2. Concern on the impact of a DMARD on reproductive health
“Could any of my partner’s medicines cause abnormalities in my child: prednisone, methotrexate, leflunomide?”
4.3 4.7 2.4
3. Storage, handling and stability of a specified DMARD
“How do I know if Humira (adalimumab) is okay if it was left out of the fridge for over 24 h?”
1.5 0 8.0
4. Concern about the safety of contact with a DMARD user
“Can my daughter have contact with pregnant women or children if she is on methotrexate?”
1.0 1.3 0.2
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which get scabby and burn?” Other sub-themes involved
callers asking about the safety of their DMARD in gen-
eral; and those seeking reassurance on the use of their
DMARD (Table 3).
Potential interactions with DMARDs (22.4%) were the
second major consumer focus, with most queries con-
cerning cDMARDs. Callers enquired about possible in-
teractions between their DMARD (or one proposed for
use) with their other medicines. These queries most
commonly involved nonsteroidal anti-inflammatory
drugs (NSAIDs), cardiovascular and central nervous sys-
tem agents, vaccines, and complementary medicines.
The likelihood of an interaction between a DMARD with
food, alcohol, smoking, or recreational substances such
as ecstasy was also raised.
In 13% of narratives, callers were seeking a DMARD-
related therapeutic strategy. These themes primarily in-
volved cDMARDs. Some calls referred to a relatively-
immediate action regarding the timing, dose, or adminis-
tration of a specified DMARD, while other queries fo-
cused on the dosing and timing of a concomitant
medicine in relation to DMARD therapy (mostly folic
acid and methotrexate). Although less frequent, there
were key subthemes where callers requested a strategy
to manage their DMARD in a range of circumstances:
where the DMARD was to be withdrawn or reintro-
duced; whether the medicine should be withdrawn after
an adverse event; and clarification of appropriate timing
of the DMARD dose before or after a procedure, for ex-
ample: “Can I take my methotrexate dose today if I have
just had a local anaesthetic at my dentist?”
The final major theme involved callers seeking informa-
tion on a specified DMARD. While these constituted only
10.1% of narratives, there was a strong question focus on
bDMARDs. One third of all requests for further information
concerning the then-novel bDMARDs were generated by
discussion in the media. We detected two waves of calls fol-
lowing two distinct television reports, each discussing the
introduction of a new bDMARD for the treatment of arth-
ritis. Callers’ enquiries ranged from questions about this
“new injectable drug” they “heard about on TV news” to
statements such as “they said it is a new wonder drug”. Of
note, very few callers sought to clarify “is it for me?” or “is
enough known?” Related subthemes were callers seeking:
general information about a specific DMARD; information
on the availability, cost, and logistics to access a DMARD;
and the restrictions and requirements to obtain a subsidized
DMARD, for example: “I’ve been on Remicade (infliximab)
for the last 18 months, can I get it cheaper than $800?”
Four minor but noteworthy themes also emerged from
this narrative analysis. The first was where callers sought
assistance to quantify the benefit versus harm of a speci-
fied DMARD (7.5%), conventional or biological. In some
cases, this was to compare different DMARDs for a given
clinical scenario: “Which is the better treatment for
rheumatoid arthritis: Enbrel (etanercept) or Humira (ada-
limumab)?” or to probe for an alternative with better effi-
cacy and or less side effects: “Humira (adalimumab) – is
it more effective or have less side effects?”
Another issue of significant concern for callers was the
potential impact of a DMARD on reproductive health
(4.3%), with a general overestimation of risk. This theme
included narratives about the safety of various
DMARDs:
▪ In the period prior to conception, for example: “How
long after methotrexate can I try to become pregnant?”
▪ For either gender at different time points during
pregnancy: “My partner has been taking methotrexate
(25mg per week) and I have fallen pregnant. Will the
baby be affected?”
▪ During breastfeeding: “Would Plaquenil
(hydroxychloroquine) be likely to cause my five-week old
breastfed baby to still be jaundiced?” and “Can I
continue breastfeeding my baby if I have been prescribed
sulfasalazine and prednisolone for rheumatoid
arthritis?”
▪ In relation to environmental exposure: “Am I going to
be a concern to my pregnant daughter because I am
taking weekly methotrexate?” Callers were also anxious
about the negative impact of a DMARD on male
fertility: “What is the effect of taking methotrexate on
sperm?”
Storage, handling and stability of a specified DMARD
constituted a minor theme (1.5% DMARDs and 8%
bDMARDs). Callers wanted information about the stability
of a biologic after removing it from the fridge or after freez-
ing and defrosting it, for example: “Can I still use Humira
(adalimumab) if it was completely frozen for twelve hours
but has since defrosted and looks perfectly normal?” Some
callers were also looking for solutions to keep their medi-
cine at an appropriate temperature while traveling: “How is
best to store my etanercept if I am going overseas?”
Finally, some callers were concerned about the safety
of coming in contact with a DMARD user, specifically
children and immunocompromised persons. This theme
included questions such as “Do I need to stay away from
my grandchild after being administered low-dose metho-
trexate?” and “If I take Methoblastin (methotrexate) will
I be unable to touch my animals or family and friends?”
Discussion
The calls to the MCC demonstrate that consumers have
many unanswered questions and considerable uncertainty
regarding their DMARDs. Uncertainty is acknowledged as
an integral component of health and illness [25]. It manifests
when situations are ambiguous, complex or unpredictable;
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when information is inadequate or inconsistent; and when
people feel insecure in their own state of knowledge or the
state of knowledge in general [26]. A key strategy to cope or
manage uncertainty is information seeking [25, 27, 28]. This
is consistent with our study findings where DMARD infor-
mation seeking was motivated by callers needing a second
opinion, being concerned about a worrying symptom and/or
having inadequate or conflicting information. This often oc-
curs in chronic disease where more information sources
may be accessed and there is a greater opportunity to en-
counter inconsistent information [29]. This may potentially
cause increased patient anxiety [30] and altered risk percep-
tion [31]. Conflicting information can also impact negatively
on adherence and cause patients to alter their medication
regimen without consulting their physician [32].
In addition to information seeking, callers requested im-
mediate therapeutic strategies from a trusted source to
manage various situations including dosing of DMARDs
and concomitant medicines, withdrawal, management of
an adverse event, and the interruption of medication for
surgical procedures. This suggests that it can be a chal-
lenge for consumers to access reliable DMARD informa-
tion; this poor access may be perceived as a barrier to
meeting their health information needs and achieving
their therapeutic goals [33].
In Australia, patients with a chronic disease often need
to travel large distances to visit a doctor. In our study,
DMARD-related callers emanated from every state and
territory, including rural and remote areas. The MCC
provided an accessible alternative for people who were
seeking anonymity but required timely medicines infor-
mation from a trusted source [34].
Most enquiries were generated by female callers. This is
consistent with health information seeking literature, where
women generally seek medicines information more often
than males [35, 36]. The majority of patients were also
female which reflects the general nature of autoimmune
diseases treated by DMARDs [37]. There were more calls
from the patients themselves regarding DMARDs than in
ROC, which potentially reflects ownership of their condi-
tion and higher involvement in management, a trait con-
sistent across many chronic diseases such as RA [38, 39].
Most consumers were motivated to proactively
information-seek due to perceived risks of DMARDs,
with many seeking assistance from the MCC pharmacist
to assess the risks and benefits of their DMARD. Callers
sought clarification about potential side effects and a
therapeutic strategy to manage DMARD use. Patients
with inflammatory arthropathies in various populations
often overestimate the risk of side effects, particularly
with long-term treatment [6, 8, 40, 41]. Safety as a goal
of medicines information seeking is supported by con-
sumer medicines information needs literature [42]. High
fear scores can reduce adherence and potentially impede
clinical outcomes [43–45]. In our DMARD cohort, many
callers expressing their concern of taking the medicine
resulted from reading the consumer package insert.
Since 1993, Australian legislation requires all new pre-
scription and pharmacist-only medicines to be accom-
panied by a package insert, Consumer Medicines
Information (CMI), prepared by the sponsor. These aim
to provide consumers with accurate, unbiased, and easy
to understand medicines information for informed
decision-making [46]. While CMI layout is guided by le-
gislation, it does not mandate quality and consistency of
content [47]. There is no requirement for the sponsor to
routinely update CMI to reflect information currency or
adequately address risk in special populations. These fac-
tors may contribute to consumer confusion and in some
cases cause fear [48]. Current CMI for various bDMARDs
in Australia, also available to the public on the Australian
Therapeutic Goods Administration website, report on the
frequency of serious undesirable effects, particularly ser-
ious infections and malignancies, based on their original
clinical trials [49]. However, over the last 20 years evidence
from larger registry populations using bDMARDs have
demonstrated the safety of these medicines [5]. This rela-
tively high safety profile is not reflected in the official ma-
terial that patients may read. The situation is similar for
the Summary of Product Characteristics used in Europe
and the Package Label used in the United States and may
contribute to the public’s overestimation of risk with this
medicines class.
A key concern raised by consumers was DMARD drug
interactions where the major medicines were another
DMARD, NSAIDs, cardiovascular and central nervous
system agents, vaccines, and complementary medicines.
The concomitant use of these medicines in inflammatory
arthropathies is common. Studies have not previously
identified this consumer concern [50–53].
In addition to caller focus on potential DMARD side-
effects and interactions, we observed the impact of the
media during the emergence of bDMARD availability in
Australia. These calls indicated consumer overestimation
of effectiveness. Hoffman and Del Mar conducted a
comprehensive systematic review of studies that quanti-
tatively assessed patients’ expectations of the benefits
and/or harms of any treatment, test, or screening test
[52]. They found participants rarely had accurate expec-
tations of benefits and harms, and for many interven-
tions, they had a tendency to overestimate benefits and
underestimate harms. For the two studies that measured
medicine expectations for the bDMARD infliximab in
inflammatory bowel disease [54, 55], at least half of par-
ticipants overestimated benefit in eight of ten outcomes.
The authors suggested that there appeared to be overly
optimistic expectations by the public for novel medica-
tions, particularly in chronic diseases with no cure.
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These authors and others suggest that this overesti-
mation of efficacy may enable patients to meet their psy-
chological needs such as hope, safety, a sense of control,
action, and reassurance [55].
Callers to the MCC in our study were concerned
about the potential effect of DMARDs on reproductive
health; not only maternal but also paternal exposure to
DMARDs before conceiving and during pregnancy. This
is an area of concern for patients that is under-
investigated in the literature. Many women of childbear-
ing age with a chronic disease necessitating the use of
DMARDs have difficulties finding adequate information
related to pregnancy planning, pregnancy, and early par-
enting [56]. The effects of DMARDs on male
reproduction is an even more neglected area, with sparse
data on spermatogenesis and the effects on offspring
[57]. Callers were worried about being in contact with
other persons and animals, demonstrating patients’ per-
ceptions of their medicines as potent and potentially
toxic. This suggests that a greater effort to deliver
targeted information in this domain is required.
Callers sought assistance to assess the benefit-risk bal-
ance of their DMARDs. This may, in part, be explained
by the considerable mismatch between physicians’ and
patients’ perspectives and preferences in the manage-
ment of inflammatory arthropathies [58–61]. Others
were interested in the availability, cost, and subsidised
access to DMARDs - crucial information for patients
with chronic conditions on relatively expensive medi-
cines. The restrictions to limit access to subsidised treat-
ments may add a layer of complexity to patients through
their disease journey.
Strengths and weaknesses
This is the first study to analyse real-life consumers’ in-
formation needs and concerns about DMARDs via a
caller helpline. These enquiries were initiated pro-
actively, predominately by the patients themselves or a
significant other (family, friend, carer), for a genuine
medicines information gap or concern related to a con-
ventional or biologic DMARDs. Unlike other observa-
tional studies, where patients are invited to identify areas
of concern or information needs through a question-
naire, interview or focus group, this study is a real-time
capture of a population of DMARDs users. These callers
had a genuine medicines information need unanswered
in their usual physician-patient encounters or through
other traditional sources where their uncertainty was
sufficient to motivate them to actively help-seek. The
longitudinal nature of the data captured over 8 years,
including the timeframe when the use of bDMARDs
became available, provide an understanding of how con-
sumers might manage uncertainty associated with novel
and expensive medicines.
This study has limitations, including that the MCC re-
pository contains data collected as part of a health ser-
vice which was not developed for research purposes. As
such, variables of interest to future researchers may not
be held in the database. DMARDs were extracted from
the database using ATC codes; therefore, cases could
not be consistently assessed by a specific DMARD indi-
cation, such as RA. Secondly, while the coding that
emerged from the DMARD qualitative analysis was not
validated by consumers, the coding framework and ap-
proach for MCC narrative analysis had previously been
validated by consumer representatives and other key
stakeholders on the MCC governance committee.
MCC callers represent only a part of the total group of
DMARDs users in Australia. However, the representa-
tion of calls was comparable to ROCs, originating from
all states and territories and across metropolitan, rural
and remote areas. Following on from data completion in
2010, further DMARDs particularly bDMARDs and the
targeted synthetic DMARDs have become available for
use in Australia and data on these newer agents are
therefore lacking [62, 63]. Furthermore, patients are
more frequently accessing information regarding their
medicines from various sources, predominantly online
and through social media [64]. This increased exposure
to information, as well as the inaccuracies and low read-
ability of the content of many unreliable resources [65],
may create different information gaps and concerns
among patients not identified by our study.
Conclusion
This study demonstrates that consumers have consider-
able uncertainty regarding DMARDs and they may over-
emphasise risk. Patients cautiously assess the benefits
and risks of their DMARDs but when new treatments
emerge, they tend to overestimate their effectiveness.
Understanding the common themes driving medicines
information-seeking related to DMARDs is key to ad-
dressing consumer information gaps and improving
overall DMARD use and adherence.
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